Physician profile
Percy D Mitchell
NPI 1326106436
$3,406.99
in general payments reported to CMS, 2019-2025
21 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $207 · 2021: $422 · 2022: $345 · 2023: $656 · 2024: $720 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $433.13 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $306.80 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $273.54 | 2019-2022 | |
| Alkermes, INC. | $248.14 | 2019-2025 | Aristada, Lybalvi |
| Corium, LLC | $238.34 | 2021-2024 | Azstarys |
| Allergan, INC. | $217.77 | 2019-2020 | |
| Lundbeck LLC | $180.75 | 2019-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $147.11 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.28 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $42.48 | 2019-2022 | |
| Shire North American Group INC | $40.27 | 2019 | |
| Adlon Therapeutics L.P. | $31.85 | 2020 | |
| Almatica Pharma LLC | $26.20 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $25.25 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.78 | 2020 | |
| Axsome Therapeutics, INC. | $16.99 | 2023 | Auvelity |
| Indivior INC. | $14.99 | 2023 | Perseris |
| Collegium Pharmaceutical, INC. | $14.92 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $14.63 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.09 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Percy Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.